NCT00573508View on ClinicalTrials.gov

Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life

PHASE4CompletedINTERVENTIONAL
Enrollment

768

Participants

Timeline

Start Date

August 31, 2007

Primary Completion Date

July 31, 2008

Study Completion Date

July 31, 2008

Conditions
Urinary Bladder, Overactive
Interventions
DRUG

Placebo

Oral Administration

DRUG

Solifenacin Succinate

Oral Administration

Trial Locations (59)

10016

New York

10029

New York

11530

Garden City

12401

Kingston

12601

Poughkeepsie

13760

Endwell

14127

Orchard Park

15401

Uniontown

19114

Philadelphia

19611

West Reading

27103

Winston-Salem

27612

Raleigh

28025

Concord

29650

Greer

29681

Simpsonville

30076

Roswell

32308

Englewood

Tallahassee

33324

Plantation

33414

Wellington

33607

Tampa

33613

Tampa

33761

Clearwater

36067

Montgomery

44124

Lyndhurst

45212

Cincinnati

47130

Jeffersonville

53703

Madison

58104

Fargo

59102

Billings

60160

Melrose Park

67080

Waterbury

68114

Omaha

71106

Shreveport

73034

Edmond

76017

Arlington

76021

Bedford

77024

Houston

78414

Corpus Christi

78759

Austin

80012

Aurora

80211

Denver

80220

Denver

83404

Idaho Falls

85051

Phoenix

85741

Tucson

90620

Buena Park

92108

San Diego

92404

San Bernardino

93720

Fresno

95608

Carmichael

95825

Sacramento

97502

Central Point

98043

Mount Lake

98405

Tacoma

99202

Spokane

02472

Watertown

07631

Englewood

08648

Lawrenceville

Sponsors
All Listed Sponsors
lead

Astellas Pharma Inc

INDUSTRY

NCT00573508 - Study of VESIcare® In Overactive Bladder (OAB) Subjects to Evaluate Symptom Bother and Health Related Quality of Life | Biotech Hunter | Biotech Hunter